Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts
Parkinson’s Disease (PD) is characterized both by the loss of dopaminergic neurons in the substantia nigra and the presence of cytoplasmic inclusions called Lewy Bodies. These Lewy Bodies contain the aggregated α-synuclein (α-syn) protein, which has been shown to be able...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-03-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/10/3/391 |
| _version_ | 1819240345644302336 |
|---|---|
| author | Margaux Teil Marie-Laure Arotcarena Emilie Faggiani Florent Laferriere Erwan Bezard Benjamin Dehay |
| author_facet | Margaux Teil Marie-Laure Arotcarena Emilie Faggiani Florent Laferriere Erwan Bezard Benjamin Dehay |
| author_sort | Margaux Teil |
| collection | DOAJ |
| description | Parkinson’s Disease (PD) is characterized both by the loss of dopaminergic neurons in the substantia nigra and the presence of cytoplasmic inclusions called Lewy Bodies. These Lewy Bodies contain the aggregated α-synuclein (α-syn) protein, which has been shown to be able to propagate from cell to cell and throughout different regions in the brain. Due to its central role in the pathology and the lack of a curative treatment for PD, an increasing number of studies have aimed at targeting this protein for therapeutics. Here, we reviewed and discussed the many different approaches that have been studied to inhibit α-syn accumulation via direct and indirect targeting. These analyses have led to the generation of multiple clinical trials that are either completed or currently active. These clinical trials and the current preclinical studies must still face obstacles ahead, but give hope of finding a therapy for PD with time. |
| first_indexed | 2024-12-23T14:06:32Z |
| format | Article |
| id | doaj.art-1b03d8688f914a31b6cf455ef5c8dfd1 |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-12-23T14:06:32Z |
| publishDate | 2020-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-1b03d8688f914a31b6cf455ef5c8dfd12022-12-21T17:44:10ZengMDPI AGBiomolecules2218-273X2020-03-0110339110.3390/biom10030391biom10030391Targeting α-synuclein for PD Therapeutics: A Pursuit on All FrontsMargaux Teil0Marie-Laure Arotcarena1Emilie Faggiani2Florent Laferriere3Erwan Bezard4Benjamin Dehay5Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, FranceUniv. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, FranceUniv. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, FranceUniv. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, FranceUniv. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, FranceUniv. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, FranceParkinson’s Disease (PD) is characterized both by the loss of dopaminergic neurons in the substantia nigra and the presence of cytoplasmic inclusions called Lewy Bodies. These Lewy Bodies contain the aggregated α-synuclein (α-syn) protein, which has been shown to be able to propagate from cell to cell and throughout different regions in the brain. Due to its central role in the pathology and the lack of a curative treatment for PD, an increasing number of studies have aimed at targeting this protein for therapeutics. Here, we reviewed and discussed the many different approaches that have been studied to inhibit α-syn accumulation via direct and indirect targeting. These analyses have led to the generation of multiple clinical trials that are either completed or currently active. These clinical trials and the current preclinical studies must still face obstacles ahead, but give hope of finding a therapy for PD with time.https://www.mdpi.com/2218-273X/10/3/391parkinson’s disease, α-synucleinneurodegenerationtherapyaggregation |
| spellingShingle | Margaux Teil Marie-Laure Arotcarena Emilie Faggiani Florent Laferriere Erwan Bezard Benjamin Dehay Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts Biomolecules parkinson’s disease, α-synuclein neurodegeneration therapy aggregation |
| title | Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts |
| title_full | Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts |
| title_fullStr | Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts |
| title_full_unstemmed | Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts |
| title_short | Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts |
| title_sort | targeting α synuclein for pd therapeutics a pursuit on all fronts |
| topic | parkinson’s disease, α-synuclein neurodegeneration therapy aggregation |
| url | https://www.mdpi.com/2218-273X/10/3/391 |
| work_keys_str_mv | AT margauxteil targetingasynucleinforpdtherapeuticsapursuitonallfronts AT marielaurearotcarena targetingasynucleinforpdtherapeuticsapursuitonallfronts AT emiliefaggiani targetingasynucleinforpdtherapeuticsapursuitonallfronts AT florentlaferriere targetingasynucleinforpdtherapeuticsapursuitonallfronts AT erwanbezard targetingasynucleinforpdtherapeuticsapursuitonallfronts AT benjamindehay targetingasynucleinforpdtherapeuticsapursuitonallfronts |